Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Are adverse drug reaction patterns different between romiplostim and eltrombopag? 2009-2013 French PharmacoVigilance assessment.
Moulis G, Bagheri H, Sailler L, Jonville-Bera AP, Weber E, Guy C, Petitpain N, Laroche ML, Favrelière S, Béné J, Baldin B, Villeval-Federici L, Tebacher-Alt M, Bres V, Veyrac G, Grandvuillemin A, Mauprivez C, Lapeyre-Mestre M, Montastruc JL; French Association of PharmacoVigilance Centers. Moulis G, et al. Among authors: veyrac g. Eur J Intern Med. 2014 Oct;25(8):777-80. doi: 10.1016/j.ejim.2014.09.006. Epub 2014 Sep 18. Eur J Intern Med. 2014. PMID: 25242516
Safety surveillance of influenza A(H1N1)v monovalent vaccines during the 2009-2010 mass vaccination campaign in France.
Caillet C, Durrieu G, Jacquet A, Faucher A, Ouaret S, Perrault-Pochat MC, Kreft-Jaïs C, Castot A, Montastruc JL; French Network of Pharmacovigilance Centres. Caillet C, et al. Eur J Clin Pharmacol. 2011 Jun;67(6):649-51. doi: 10.1007/s00228-010-0961-8. Epub 2010 Dec 14. Eur J Clin Pharmacol. 2011. PMID: 21153631 No abstract available.
First French experience of ADR reporting by patients after a mass immunization campaign with Influenza A (H1N1) pandemic vaccines: a comparison of reports submitted by patients and healthcare professionals.
Durrieu G, Palmaro A, Pourcel L, Caillet C, Faucher A, Jacquet A, Ouaret S, Perault-Pochat MC, Kreft-Jais C, Castot A, Lapeyre-Mestre M, Montastruc JL; French Network of Pharmacovigilance Centres. Durrieu G, et al. Drug Saf. 2012 Oct 1;35(10):845-54. doi: 10.1007/BF03261980. Drug Saf. 2012. PMID: 22967189
The PREGVAXGRIP study: a cohort study to assess foetal and neonatal consequences of in utero exposure to vaccination against A(H1N1)v2009 influenza.
Chavant F, Ingrand I, Jonville-Bera AP, Plazanet C, Gras-Champel V, Lagarce L, Zenut M, Disson-Dautriche A, Logerot S, Auffret M, Coubret-Dumas A, Bruel ML, Boyer M, Bos-Thompson MA, Veyrac G, Carlier P, Beyens MN, Lates S, Damase-Michel C, Castot A, Kreft-Jaïs C, Pérault-Pochat MC. Chavant F, et al. Among authors: veyrac g. Drug Saf. 2013 Jun;36(6):455-65. doi: 10.1007/s40264-013-0030-1. Drug Saf. 2013. PMID: 23516007
Liquid formulation of ifosfamide increased risk of encephalopathy: A case-control study in a pediatric population.
Hillaire-Buys D, Mousset M, Allouchery M, Azzouz B, Babin M, Bellet F, Béné J, Default A, Durrieu G, Géniaux H, Grandvuillemin A, Gras-Champel V, Jantzem H, Lambert A, Lepelley M, Massy N, Petitpain N, Rocher F, Sanchez-Pena P, Sassier M, Simon C, Triquet L, Valnet-Rabier MB, Veyrac G, Faillie JL, Zenut MC. Hillaire-Buys D, et al. Among authors: veyrac g. Therapie. 2020 Sep-Oct;75(5):471-480. doi: 10.1016/j.therap.2019.08.001. Epub 2019 Oct 28. Therapie. 2020. PMID: 31732241
Adverse Drug Reactions in Pediatric Emergency Medicine.
Darnis D, Mahé J, Vrignaud B, Guen CG, Veyrac G, Jolliet P. Darnis D, et al. Among authors: veyrac g. Ann Pharmacother. 2015 Dec;49(12):1298-304. doi: 10.1177/1060028015602904. Epub 2015 Aug 31. Ann Pharmacother. 2015. PMID: 26324354
48 results